Evolus Q2 2024 Earnings Report $13.99 -0.63 (-4.31%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Evolus EPS ResultsActual EPS-$0.14Consensus EPS -$0.12Beat/MissMissed by -$0.02One Year Ago EPSN/AEvolus Revenue ResultsActual Revenue$66.91 millionExpected Revenue$65.06 millionBeat/MissBeat by +$1.85 millionYoY Revenue GrowthN/AEvolus Announcement DetailsQuarterQ2 2024Date7/31/2024TimeN/AEOLS Upcoming EarningsEvolus will be holding an earnings conference call on Tuesday, March 4 at 4:30 PM Eastern. Interested parties can register for or listen to the call or dial in at 201-612-7415 using passcode "13751816". Conference Call ResourcesEOLS Earnings History Evolus Earnings HeadlinesEvolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness SummitFebruary 20 at 10:41 AM | finance.yahoo.comEvolus's SWOT analysis: FDA nod for filler boosts stock outlookFebruary 17, 2025 | msn.comShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.February 22, 2025 | Brownstone Research (Ad)Evolus' (EOLS) "Buy" Rating Reiterated at HC WainwrightFebruary 17, 2025 | americanbankingnews.comEvolus Gets FDA Approval for Two Injectable Hyaluronic Acid GelsFebruary 13, 2025 | marketwatch.comEvolus trading halted, news pendingFebruary 13, 2025 | markets.businessinsider.comSee More Evolus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email. Email Address About EvolusEvolus (NASDAQ:EOLS), a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.View Evolus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
